Drug Trial News

RSS

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

A combination of three drugs used worldwide as the standard of care for a serious lung disease puts patients in danger of death or hospitalization, and should not be used together to treat the disease, called idiopathic pulmonary fibrosis, according to the surprising results of a rigorous independent study.

21 May 2012

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

21 May 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 - 22, 2012.

19 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting.

19 May 2012

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer Inc. announced the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu.

19 May 2012

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA.

19 May 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Pharmacyclics, Inc. today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

Potential public-private partnership aims to bring TB vaccine trials to mines of Southern Africa

GlobalPost's "Global Pulse" blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, "for every 100,000 workers ..., 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB."

18 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Avraham initiates ladostigil Phase 2 trial in MCI

Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment.

18 May 2012

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

18 May 2012

Drug Trial News

Three-drug combo harmful for patients with idiopathic pulmonary fibrosis

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Data from Purdue Pharma’s Butrans clinical trials to be presented at APS annual meeting

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

Sigmoid provides financial and product development update

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Potential public-private partnership aims to bring TB vaccine trials to mines of Southern Africa

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Avraham initiates ladostigil Phase 2 trial in MCI

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News